Go­ing head-to-head with Eylea, Roche touts PhI­II win for bis­pe­cif­ic block­buster con­tender in di­a­bet­ic mac­u­lar ede­ma

Roche had its sights set on Eylea — the block­buster eye drug that es­sen­tial­ly made Re­gen­eron — ear­ly in the de­vel­op­ment pro­gram for the bis­pe­cif­ic an­ti­body faricimab, which tar­gets both the VEGF-A path­way and an­giopoi­etin-2 (Ang-2).

Now, the phar­ma gi­ant’s sub­sidiary Genen­tech says faricimab has cleared two Phase III stud­ies for di­a­bet­ic mac­u­lar ede­ma, where it went head-to-head with Eylea.

The key met­ric across the YOSEMITE and RHINE tri­als was non-in­fe­ri­or vi­su­al acu­ity gains, and sev­er­al dos­ing reg­i­mens of faricimab were com­pared against the stan­dard Eylea treat­ment, giv­en every eight weeks. Whether pa­tients took faricimab every eight weeks or at per­son­al­ized dos­ing in­ter­vals up to 16 weeks, the drug proved non-in­fe­ri­or.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.